The decrease in the amount of oral ulcers was evident by week 2 in the apremilast group and was sustained through the entire full 24-week treatment phase. An excellent response was also observed after patients who had been receiving placebo were switched to apremilast at week 12 . During the 4-week post-treatment observation stage that followed week 24, the mean amount of oral ulcers began to increase within 2 weeks. The mean number of oral ulcers at week 12 in the per-protocol population was similar to that in the intention-to-treat population and was significantly lower in the apremilast group than in the placebo group . Consistent outcomes were attained when repeated-procedures analyses were used.As a total result of its individualized nature, each Prophage vaccine intends to support the precise signals of the patient's particular tumor which is meant to engage the body's immune system to target only cancer cells bearing this type of fingerprint. Such high accuracy in immunological targeting represents a distinctly different method for treating cancer in comparison to conventional anti-cancer treatments such as chemotherapy or radiation therapy without most of the side effects seen in conventional therapy. Prophage is being studied in both newly diagnosed and recurrent GBM currently. This three-arm study of 222 individuals shall evaluate efficacy of Prophage provided with Avastin either concomitantly or at progression, versus Avastin alone.